

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SHIRE BIOCHEM INC</u> (Last) (First) (Middle) 275 ARMAND-FRAPPIER BLVD (Street) LAVAL QUEBEC E6 H7V 4A7 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 05/13/2003	3. Issuer Name and Ticker or Trading Symbol <u>IMMUNOGEN INC [IMGN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,096,098	D ⁽¹⁾	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				

1. Name and Address of Reporting Person*
SHIRE BIOCHEM INC
 (Last) (First) (Middle)
 275 ARMAND-FRAPPIER BLVD
 (Street)
 LAVAL QUEBEC E6 H7V 4A7
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SHIRE PHARMACEUTICALS GROUP PLC
 (Last) (First) (Middle)
 HAMPSHIRE INTL BUSINESS PARK
 CHINEHAM BASINGSTOKE
 (Street)
 HAMPSHIRE ENGLAND RG X0
 (City) (State) (Zip)

Explanation of Responses:

1. These shares are owned directly by Shire BioChem Inc., which is a wholly owned subsidiary of Shire Pharmaceuticals Group plc. Shire Pharmaceuticals Group plc is an indirect beneficial owner of the reported securities.

Remarks:

Exhibit 99 - Joint Filer Information

/s/ Joseph Rus, President & CEO, Shire BioChem Inc.

08/06/2003

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 3 Joint Filer Information

Name: Shire Pharmaceuticals Group plc

Address: Hampshire International Business Park
Chineham, Basingstoke
Hampshire, England RG24 8EP

Designated Filer: Shire BioChem Inc.

Issuer & Ticker Symbol: ImmunoGen, Inc. (IMGN)

Date of Event Requiring Statement: May 13, 2003

Signature: /s/ Angus Charles Russell

Name: Angus Charles Russell
Title: Group Finance Director